The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Arix to Present at the Proactive One2One Virtual Investor Forum

8 Apr 2021 07:00

Arix Bioscience PLC Arix to Present at the Proactive One2One Virtual Investor Forum 08-Apr-2021 / 07:00 GMT/BST


 

Arix Bioscience plc

 

Arix to Present at the Proactive One2One Virtual Investor Forum

 

LONDON, 08 April 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, announces that Naseem Amin, Executive Chairman, will present at the Proactive One2One Virtual Investor Forum today, Thursday, 8 April 2021 at 7:00pm BST. Arix will be one of four companies presenting on the evening, each having a presentation slot followed by Q&A, with the webinar taking place from 6.00pm.

Investors can register to attend here: https://event.webinarjam.com/register/1024/gwwg2hxq9

A replay of the presentation will be available after the event, on the investor relations section of the Arix website at https://arixbioscience.com/investor-relations/events-presentations

[ENDS]

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

 

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 

 


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1182031 08-Apr-2021 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
31st Mar 20215:39 pmEQSTransaction in own shares
30th Mar 20215:09 pmEQSTransaction in own shares
30th Mar 20211:02 pmEQSArix leads $152 million Series B financing for Pyxis Oncology
30th Mar 20217:00 amEQSGita Dittmar appointed as Venture Partner
29th Mar 20215:14 pmEQSTransaction in own shares
29th Mar 20217:00 amEQSBoard update
26th Mar 20215:14 pmEQSTransaction in own shares
25th Mar 20214:58 pmEQSTransaction in own shares
24th Mar 20215:05 pmEQSTransaction in own shares
24th Mar 20217:00 amEQSStrategy Implementation Review
23rd Mar 20215:27 pmEQSTransaction in own shares
22nd Mar 20215:57 pmEQSTransaction in own shares
22nd Mar 202111:09 amEQSAura Biosciences announces oversubscribed $80 million financing
22nd Mar 20217:00 amEQSShare buyback programme of up to £25 million
19th Mar 20214:00 pmEQSHolding(s) in Company
15th Mar 20217:30 amEQSHardman & Co Research: Arix Bioscience (ARIX): 32% IRR since inception in 2016
15th Mar 20217:00 amEQSShare buyback programme of up to £25 million
10th Mar 20217:01 amEQSResponse to Activist Shareholder Acacia
9th Mar 20217:01 amEQSArix founds new portfolio company Twelve Bio
9th Mar 20217:01 amEQSAnnual Results for the Twelve Months ended 31 December 2020
25th Feb 20217:00 amEQSBoard Changes
15th Feb 20219:00 amEQSHolding(s) in Company
11th Feb 20217:00 amEQSNotice of Results
10th Feb 20219:00 amEQSAutolus announces pricing of public offering
5th Feb 20214:41 pmRNSSecond Price Monitoring Extn
5th Feb 20214:36 pmRNSPrice Monitoring Extension
5th Feb 20219:06 amRNSSecond Price Monitoring Extn
5th Feb 20219:00 amRNSPrice Monitoring Extension
18th Jan 20217:00 amEQSInvestment team changes
12th Jan 20217:00 amEQSHarpoon announces closing of public offering
6th Jan 20212:00 pmEQSImara reports Phase 2a clinical trial results of IMR-687 in adult patients with sickle cell disease  
6th Jan 202110:00 amEQSAutolus provides business outlook for 2021 and 2022
31st Dec 20209:00 amRNSPrice Monitoring Extension
21st Dec 20207:00 amEQSDirector Share Purchase
18th Dec 20208:00 amEQSCompletion of sale of VelosBio
11th Dec 20207:00 amEQSAtox Bio announces FDA acceptance of New Drug Application
8th Dec 20203:45 pmEQSHarpoon reports clinical progress across all pipeline development programmes
7th Dec 20205:48 pmEQSAutolus presents additional data on AUTO3 at ASH
7th Dec 20207:15 amEQSHardman & Co Research: Arix Bioscience (ARIX): Artios attracts Merck KGaA in deal up to $7bn
7th Dec 20207:01 amEQSAutolus presents positive AUTO1 data at ASH
4th Dec 20207:01 amEQSHolding(s) in Company
4th Dec 20207:00 amEQSHolding(s) in Company
3rd Dec 20209:05 amRNSSecond Price Monitoring Extn
3rd Dec 20209:00 amRNSPrice Monitoring Extension
3rd Dec 20208:01 amEQSArtios and Merck KGaA announce global strategic collaboration
12th Nov 20207:00 amEQSArix to Present at the Jefferies Virtual London Healthcare Conference
6th Nov 202012:10 pmEQSHardman & Co Research: Arix Bioscience (ARIX): Hitting the jackpot
5th Nov 20202:06 pmRNSSecond Price Monitoring Extn
5th Nov 20202:00 pmRNSPrice Monitoring Extension
5th Nov 202011:38 amEQSArix Bioscience PLC: VelosBio to be acquired by Merck for $2.75 billion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.